The most useful question about a formulation chart may concern a component the chart has barely mentioned. A presentation can place one ingredient on the horizontal axis, show a response moving beside it and invite the reader to credit that ingredient with the change. If the formulation has a fixed total, something else must have moved too. That second movement is part of the experiment even when it is absent from the title. I learnt this through an interpretation I approved, rather than through a problem I merely observed in someone else's work.
Our fictional 2019 demonstration used four blends. A rose from 6% to 9%, B fell from 64% to 61%, and C remained at 30%. The intermediate blends used 7% and 63%, then 8% and 62%. Every row summed to 100%. That arithmetic was correct. The mistake was allowing a correct set of rows to support a more specific explanation than the comparison had established. I want a data leader's account of such a decision to retain that distinction, because checking totals alone would not have prevented my approval.
## The other movement inside the total
A researcher may have sound reasons for choosing that path through the possible blends. It can answer a useful question about replacing some of one component with another while holding a third proportion constant. The difficulty begins when the explanation changes into a claim about A considered independently of B. The experiment did not provide that independent movement. A label that emphasises one component can make the change of question almost invisible to a reader who is concentrating on the response.
Peter Qezvomi asked which comparison justified the separate attribution. I initially wanted to preserve the demonstration with a short qualification. Commercial colleagues had spent time finding a concise story, and the observations themselves had not become fabricated. But a qualification placed far from the chart would have asked the reader to undo the explanation the chart was designed to suggest. We needed to change the account at the point where the interpretation was being formed. That included showing the composition as a whole.
This does not mean every useful formulation study must answer every possible ingredient question. A study has a purpose, a region of feasible compositions and practical constraints. It can be valuable within those limits. The obligation is to keep its answer connected to the question it actually distinguishes. A comparison of blends should not become a claim of isolated ingredient influence merely because the latter sounds easier to communicate. Nor should an unresolved attribution be disguised as proof that no ingredient matters.
The original records therefore remained in our account. We retained each composition and its observed response, while withdrawing the standalone effect claim. Keeping the records matters because a correction should not erase the route by which the organisation reached its earlier view. A future researcher may still use them for an appropriate purpose. That possibility does not restore the rejected interpretation, and it does not authorise our software team to choose a new recipe on the customer's behalf.
## What a new study has to earn
The next step was a research-design question before it was a software-development task. Scientific colleagues needed to state what they wanted to learn, which compositions were meaningful and which response would be assessed. They also needed to consider the adequacy of the resulting model and the conditions under which it would be used. The data function could support that work by making the assumptions explicit. It could not earn a more ambitious answer simply by fitting a more elaborate line to the same limited comparison.
I find it helpful to separate three proposed actions in an investment discussion. We may want to explain the existing observations more accurately. We may want to collect new observations capable of answering another question. Or we may want to develop a product feature that helps customers organise future studies. Those actions can support each other, but they have different costs and completion conditions. Finishing the first does not establish that the second has succeeded, and releasing the third does not validate every study a customer might conduct.
Our response included ₹32 lakh for review and a revised design. That was a commitment to do the work needed for a better-founded enquiry. It was not a price paid to make the original conclusion true. I wanted the approval paper to distinguish the withdrawn claim, the retained observations and the proposed research. Otherwise the correction could have been reported as a single completed improvement while the scientific question remained open. The board deserved to see what had actually changed and what still required an answer.
There is also a practical boundary around the data leader's authority. I can organise the representation of compositions, the recording of study conditions and the way our product presents a result. I can challenge an explanation whose supporting comparison is unclear. I do not thereby become the relevant scientist for every formulation or the authority responsible for a finished product. A useful leadership account names that boundary without using it to avoid responsibility for the software choices I do control.
## A product decision with a research cost
The interface had encouraged a narrow reading. A prominent component value and a neighbouring result were easier to scan than the full composition. We revised the explanatory view so that the compensating movement was available where the user encountered the conclusion. This was not a demand to display every field with equal visual weight. It was a decision that context necessary to understand the particular claim could not be relegated to a place the reader had little reason to inspect.
That choice carried a commercial cost. A simple demonstration was delayed, colleagues reopened work they thought was finished, and the wider interpretation could no longer be used as a convenient proposition. I resist describing such changes as automatic evidence of superior returns. They may improve the honesty and usefulness of a decision while leaving the business with additional expense and a smaller immediate story. The judgement should be assessed on those terms rather than rescued by an invented financial benefit.
For a board, the relevant question extends beyond whether management has corrected a graph. How does the enterprise decide that its product has earned a new claim? Which specialist must agree, what comparison supports the explanation and what uncertainty remains in the proposed investment? A director need not redesign the experiment during a meeting. The board does need an account in which research findings, product scope and financial expectations have not quietly become substitutes for one another.
I now ask to see the other movement inside the total before accepting the headline. That habit does not supply every answer about a blend. It changes the opening question and makes the next decision more explicit. The enduring lesson from my own approval is that a result can be recorded correctly while its explanation still asks the evidence to do too much. Software should help the reader recognise that gap, and its leaders should be willing to fund the work that a more defensible answer requires.